NOV 06, 2016 03:48 PM PST

Drug for Neglected Disease Activated by Newly Found Enzyme

WRITTEN BY: Carmen Leitch
Neglected diseases are those that affect the world’s poor and are usually common in tropical areas. A new discovery could aid in the treatment of one such disease, Visceral leishmaniasis (VL) which is also known as Kala-azar. Researchers at the University of Dundee in New Zealand, an area of research on neglected diseases, have found a protein that can help improve the efficacy of a drug that was recently identified as a therapeutic for VL.
 

VL, described in the video above, that affects roughly two to four hundred thousand people globally, according to the Centers for Disease Control. It is a parasitic infection that can range from a silent infection, with no symptoms, to more serious cases of fever, weight loss and liver and spleen problems. It primarily affects people in Brazil, India, Nepal, Bangladesh, Ethiopia, South Sudan and Sudan. The current treatments have considerable limitations such as high cost, toxicity, side effects, prolonged administration and drug resistance; there are no vaccines.
 
"There has been considerable interest in developing new compounds to target diseases like leishmaniasis, particularly because the existing drugs are very unsatisfactory and increasingly becoming unusable due to resistance in the parasite," said Professor Alan Fairlamb, Wellcome Principal Research Fellow in the School of Life Sciences at Dundee. He is the senior author of the work, reported in PLOS Pathogens.
 
Fairlamb, in collaboration with Dr. Kevin Read and colleagues have previously shown that one drug used to treat tuberculosis, called delamanid, can potentially also treat VL. Their new work with a team at the Wellcome Trust Sanger Institute in Cambridge, UK, identified a protein that is characterized as a nitroreductase – an enzyme that targets nitrogen compounds, and shows that it can improve the efficacy of delamanid as a VL nitro-drug. An example of a nitroreductase is shown below.
 

 
The researchers term the newly found protein nitroreductase NTR2. The researchers show that it can result in hypersensitivity to bicyclic nitro compounds like delamanid. Another type of nitroreductase, NTR1, activates other types of nitrogen compounds, monocyclic nitro-drugs.
 
"One concern has been that if all nitro-drugs are activated by NTR1, then loss of this protein would lead to widespread drug resistance to both unicyclic drugs (fexinidazole) and bicyclic drugs (delamanid). We have discovered this new protein, NTR2 that specifically activates drugs like delamanid but not fexinidazole," explained Fairlamb
 
"This knowledge is extremely important in that it allows us to design better drugs activated by NTR2 and to suggest drug combinations that will reduce the risk of emergence of drug resistance through loss of either NTR1 or NTR2 activity. It also provides a potential diagnostic marker for resistance should it arise," said Fairlamb.
 
One drug identified by the researchers, fexinidazole, is undergoing phase II clinical trials in Africa as part of the Drugs for Neglected Diseases initiative. Delamanid has been considered for immediate trials in VL patients.
 
"Further work is now needed to find the most appropriate partner drugs to be used to increase efficacy and decrease toxicity in patients, to minimize the risk of drug resistance emerging and in designing second generation drugs.” Fairlamb concluded.

If you would like to know more about neglected disease of the world, watch the following video.
 

 
Sources: AAAS/Eurekalert! via Dundee University, PLOS Pathogens
 
About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
SEP 18, 2019
Genetics & Genomics
SEP 18, 2019
New Insights Into the Role of Enhancers in Gene Regulation
Researchers have uncovered a new set of rules that govern cellular decision-making about gene activation....
SEP 18, 2019
Genetics & Genomics
SEP 18, 2019
Tools for Easily Analyzing DNA-Protein Interactions
Scientists have improved on a recently-developed method for visualizing the interactions between DNA and proteins....
SEP 18, 2019
Genetics & Genomics
SEP 18, 2019
Rethinking What we Know About Gene Control
Researchers are taking a new look at how the cell regulates gene expression....
SEP 18, 2019
Immunology
SEP 18, 2019
New Research In Reversing Deafness
Hair cells inside the human ear are responsible for sensing and relaying sound to the brain.  In all mammals except humans, these cells can regenerate...
SEP 18, 2019
Genetics & Genomics
SEP 18, 2019
Investigating Previously Unmapped Regions of the Human Genome
Researchers have used cutting edge imaging tools to map a region of the human genome that has not been well-described....
SEP 18, 2019
Cell & Molecular Biology
SEP 18, 2019
How the Kava Plant Creates Medicinal Compounds
Nature has given us some of our best medicines; it's thought that as many as half the drugs we used are derived from natural products....
Loading Comments...